Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

ACTAVIS INC
Mes dernières consult.
Most popular
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Watson Says Received Favorable Ruling Over Generic Sanctura XR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/04/2012 | 12:19am CEST

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ACTAVIS INC
08/22 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Al..
08/16 ALLERGAN : to Present at the 2017 Wells Fargo Healthcare Conference
08/16 ALLERGAN CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of L..
08/16 ALLERGAN PLC : ex-dividend day
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second-q..
08/14 Big-name U.S. hedge funds shed healthcare stocks during the rally in second q..
08/12 ALLERGAN SHAREHOLDER ALERT BY FORMER : Kahn Swick & Foti, LLC Reminds Investors ..
08/10 AMGEN : And Allergan Submit Biosimilar Biologics License Application For ABP 980..
08/09 ALLERGAN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
08/09 ALLERGAN SHAREHOLDER ALERT BY FORMER : Kahn Swick & Foti, LLC Reminds Investors ..
More news
Financials ($)
Sales 2017 15 924 M
EBIT 2017 7 642 M
Net income 2017 -3 114 M
Debt 2017 24 449 M
Yield 2017 1,31%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 6,23x
EV / Sales 2018 5,74x
Capitalization 74 801 M
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 266 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC74 801
JOHNSON & JOHNSON15.83%358 180
NOVARTIS7.89%216 850
ROCHE HOLDING LTD.3.78%215 061
PFIZER2.06%195 090
MERCK AND COMPANY6.03%169 014